Clinical Cancer Research, Vol 2, Issue 8 1417-1425, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Endogenous interleukin 6 can function as an in vivo growth- stimulatory factor for advanced-stage human melanoma cells

C Lu, C Sheehan, JW Rak, CA Chambers, N Hozumi and RS Kerbel
Division of Cancer Biology Research, Reichmann Research Building, Sunnybrook Health Science Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5.

We have previously shown that a majority of human melanoma cell lines derived from early-stage lesions were growth inhibited by exogenous interleukin 6 (IL-6) in vitro, whereas cell lines from advanced-stage lesions were resistant to such IL-6-induced growth inhibition. Among the resistant melanoma cell lines, 50-60% constitutively produced IL-6, which appeared to function as a growth stimulator in vitro, based on the growth-suppressive effects of antisense oligonucleotides to the IL-6 gene. The present study was primarily aimed at evaluating whether endogenous IL-6 also functions in vivo as a growth modulator for IL-6-producing and -nonproducing melanoma cells. To do so, we first introduced an IL-6 expression vector into IL-6-nonproducing human melanoma cells using WM35, an early-stage (radial growth phase) cell line, the growth of which is normally inhibited by IL-6, and WM983A, an advanced-stage cell line, the growth of which in vitro is not affected by exogenous IL-6. None of the IL-6-producing transfectants showed a significant alteration in tumor growth in nude mice. Next, two IL-6-producing melanoma cell lines, both of which were derived from metastases, MeWo and WM9, and which are growth resistant to exogenously added IL-6, were transfected with an antisense IL-6 expression vector. Several transfectant clones manifested a constitutive decrease in IL-6 gene expression and protein production, and they also gave rise to much smaller tumors with slower growth rates and longer latency periods. However, these IL-6 antisense transfectants were not growth suppressed in in vitro cell cultures, relative to their respective parental controls. Taken together, the results demonstrate that endogenous IL-6 can indeed function as a growth stimulator for human cutaneous melanomas in vivo. This growth-stimulatory or survival mechanism remains to be clarified but may be paracrine rather than autocrine in nature.

This article has been cited by other articles:

				S. Kreis, G. A. Munz, S. Haan, P. C. Heinrich, and I. Behrmann Cell Density Dependent Increase of Constitutive Signal Transducers and Activators of Transcription 3 Activity in Melanoma Cells Is Mediated by Janus Kinases Mol. Cancer Res., December 1, 2007; 5(12): 1331 - 1341. [Abstract] [Full Text] [PDF]

				A. Anichini, A. Scarito, A. Molla, G. Parmiani, and R. Mortarini Differentiation of CD8+ T Cells from Tumor-Invaded and Tumor-Free Lymph Nodes of Melanoma Patients: Role of Common {gamma}-Chain Cytokines J. Immunol., August 15, 2003; 171(4): 2134 - 2141. [Abstract] [Full Text] [PDF]

				H. Steiner, S. Godoy-Tundidor, H. Rogatsch, A. P. Berger, D. Fuchs, B. Comuzzi, G. Bartsch, A. Hobisch, and Z. Culig Accelerated in Vivo Growth of Prostate Tumors that Up-Regulate Interleukin-6 Is Associated with Reduced Retinoblastoma Protein Expression and Activation of the Mitogen-Activated Protein Kinase Pathway Am. J. Pathol., February 1, 2003; 162(2): 655 - 663. [Abstract] [Full Text] [PDF]

				M. K. Pathak, D. Dhawan, D. J. Lindner, E. C. Borden, C. Farver, and T. Yi Pentamidine Is an Inhibitor of PRL Phosphatases with Anticancer Activity Mol. Cancer Ther., December 1, 2002; 1(14): 1255 - 1264. [Abstract] [Full Text] [PDF]

				F. Benchetrit, A. Ciree, V. Vives, G. Warnier, A. Gey, C. Sautes-Fridman, F. Fossiez, N. Haicheur, W. H. Fridman, and E. Tartour Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism Blood, March 15, 2002; 99(6): 2114 - 2121. [Abstract] [Full Text] [PDF]

				T. Yamaguchi, H. Kimura, S. Yokota, Y. Yamamoto, T. Hashimoto, M. Nakagawa, M. Ito, and T. Ogura Effect of IL-6 Elevation in Malignant Pleural Effusion on Hyperfibrinogenemia in Lung Cancer Patients Jpn. J. Clin. Oncol., February 1, 2000; 30(2): 53 - 58. [Abstract] [Full Text] [PDF]

				E. Tartour, F. Fossiez, I. Joyeux, A. Galinha, A. Gey, E. Claret, X. Sastre-Garau, J. Couturier, V. Mosseri, V. Vives, et al. Interleukin 17, a T-cell-derived Cytokine, Promotes Tumorigenicity of Human Cervical Tumors in Nude Mice Cancer Res., August 1, 1999; 59(15): 3698 - 3704. [Abstract] [Full Text] [PDF]